More on splitting up Pfizer (PFE +1.9%) (previous): Goldman Sachs' Jami Rubin sees a split of...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

More on splitting up Pfizer (PFE +1.9%) (previous): Goldman Sachs' Jami Rubin sees a split of the company's generic drug unit from its brand-name division as a dramatic way to unlock value. After crunching the numbers the analyst comes up with a sum-of-the-parts valuation on a split-up PFE of $33 a share - even before factoring in P/E expansion.